Search clinical trials for: Upadacitinib (ABT-494)

Total 4727 results

GenMont Biotech Incorporation
Kaohsiung Medical University Chung-Ho Memorial Hospital

Completed

To Evaluate the Efficacy of Probiotics Toothpastes in Improvement of Gingivitis and Prevention of Periodontal Diseases Via Modulating the Oral Microbiota

Gingivitis

Taiwan
AbbVie

Recruiting

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus

United States, Japan, Puerto Rico, Switzerland, Israel, Korea, Republic of, Hungary, New Zealand, Bulgaria, Latvia, Spain, Taiwan, Slovakia, Croatia, South Africa, Australia, Poland, Portugal, Estonia, France, Lithuania, Brazil, Ger... and more
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up)

Atopic Dermatitis

United States, Australia, Belgium, Bulgaria, Canada, China, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwa... and more
Sixth Affiliated Hospital, Sun Yat-sen University

Completed

Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease

Inflammatory Bowel Diseases

China
AbbVie

Completed

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

Dry Eye Syndrome

United States
Amgen

Completed

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

Glioblastoma or Malignant Glioma

United States, Australia, Netherlands, Germany, Spain, France
Kiniksa Pharmaceuticals, Ltd.

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

Healthy Volunteers

Australia, United States
AbbVie

Completed

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Psoriatic Arthritis
Norwegian University of Science and Technology
St. Olavs Hospital; Helse Nord-Trøndelag HF

Completed

Treatment Effects From Aerobic Endurance Training and Maximal Strength Training in Patients Suffering From Schizophrenia

Cardiovascular Disease | Schizophrenia

Norway
AstraZeneca

Completed

Interaction Between ABT-335, Rosuvastatin and Warfarin

Healthy

United States
Southern Europe New Drug Organization
Clinical Trial Unit Ente Ospedaliero Cantonale

Completed

Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer (S10PANI01)

Advanced Head and Neck Squamous Cancer
Yale University

Completed

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

CTCL

United States
AbbVie (prior sponsor, Abbott)

Completed

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Australia, Israel, Poland, Ukraine
Abbott
Genentech, Inc.

Completed

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

Healthy Female Subjects

United States
King Faisal University
Mansoura University

Completed

Non-dependent Lung High Frequency Positive Pressure Ventilation (HFPPV) and Right Ventricular Function

Lung Diseases | Esophageal Diseases

Egypt
BioLite, Inc.

Not yet recruiting

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Triple Negative Breast Cancer
MyoKardia, Inc.

Completed

Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

Dilated Cardiomyopathy | Heart Failure With Reduced Ejection Fraction

United States, France, United Kingdom, Sweden, Germany, Netherlands, Poland
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Multiple Sclerosis (MS)

United States, Canada
AbbVie
Genentech, Inc.

Completed

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Australia
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

Small Cell Lung Carcinoma | Small Cell Lung Cancer

United States, Canada, United Kingdom
Abbott

Completed

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

Hypogonadal Males

United States
Kerry Rogers
Janssen Research & Development, LLC

Withdrawn

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Chronic Lymphocytic Leukemia | Loss of Chromosome 17p
AbbVie (prior sponsor, Abbott)

Completed

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

Diabetic Neuropathies | Diabetic Neuropathy, Painful | Diabetic Polyneuropathy | Diabetic Neuralgia | Neuralgia, Diabetic

United States, Canada, France, Germany, Italy, Mexico, Puerto Rico
AbbVie

Completed

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Lymphoblastic Lymphoma | Acute Lymphoblastic Leukemia (ALL)

United States, Australia
BioLite, Inc.

Not yet recruiting

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndrome (MDS)
Tetraphase Pharmaceuticals, Inc.
Department of Health and Human Services

Completed

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women (BAL)

Normal Drug Tolerance

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
AbbVie

Not yet recruiting

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Crohn's Disease
AbbVie

Recruiting

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Ulcerative Colitis

United States, Japan, Taiwan, Spain, Korea, Republic of, Bulgaria, Italy, Poland, France, United Kingdom, Greece, New Zealand, Australia, Belgium, Israel, Hungary, Netherlands
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Chronic Lymphocytic Leukemia | Ibrutinib Resistance

United States
Jennerex Biotherapeutics

Completed

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Melanoma | Renal Cell Carcinoma | Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Innocrin Pharmaceutical
National Cancer Institute (NCI)

Completed

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

Prostate Cancer

United States
Kiniksa Pharmaceuticals, Ltd.

Active, not recruiting

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Arthritis, Rheumatoid

United States, Poland, Hungary, Georgia, Czechia, South Africa, Bulgaria
Rhythm Pharmaceuticals, Inc.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effects of RM-493 on Energy Expenditure in Obese Individuals

Obesity | Morbid Obesity

United States
National Institute of Diabetes and Digestive and...

Completed

Development of Limited Contact CBT Treatment for IBS

IBS

United States
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Abbott

Completed

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
National Cancer Institute (NCI)

Terminated

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Lung Small Cell Carcinoma | Stage IIIA Lung Small Cell Carcinoma AJCC v7 | Stage IIIB Lung Small Cell Carcinoma AJCC v7 | Stage IV Lung Small Cell... and other conditions

United States
AbbVie

Available

Expanded Access to Venetoclax

Multiple Myeloma | Non-Hodgkin's Lymphoma | Amyloidosis | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Plasma Cell Leukemia
AbbVie

Completed

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms (CisCP)

Chronic Pancreatitis

United States
Fondazione Italiana Linfomi - ETS

Terminated

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

T-Cell Lymphoma Relapsed | T-Cell Lymphoma Refractory

Italy
AbbVie

Completed

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Healthy Volunteers

United States
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

Mantle Cell Lymphoma

Australia
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
AbbVie

Withdrawn

Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer

Exocrine Pancreatic Insufficiency (EPI)
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

United States, Puerto Rico
Curis, Inc.

Recruiting

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Germany, United States, Spain, Israel, Czechia, Poland, France, Italy
MyoKardia, Inc.

Completed

A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491

Dilated Cardiomyopathy

Australia

3

Subscribe